Kramer Levin successfully represented Takeda UK Limited in the discovery phase of a foreign patent litigation in the United Kingdom involving a Roche glycosylation patent. Roche asserted the patent against Takeda’s ENTYVIO, a blockbuster treatment for ulcerative colitis and Crohn’s disease. We filed a Section 1782 proceeding to obtain discovery from Novartis in the United States concerning an antibody product sold by Novartis prior to the date of the Roche-owned patent. The UK court allowed Takeda to proceed with its novelty challenge based on the Novartis product due to the information that we obtained and issued a ruling of invalidity in favor of Takeda in July 2019.